Anthony Amato

Anthony Amato

CEO

Mr. Anthony Amato is a business leader and entrepreneurial thinker with an intuitive ability to rapidly assess challenges and identify growth opportunities. He quickly sees organizational vision and understands goals, taking appropriate ownership and action required to guide the team, achieving aggressive targets and performance levels. Anthony has hands-on executive skills at engaging and influencing key stakeholders to not only grow business but also to optimize profits.

Anthony founded InQuest Science in March 2017 and then acquired Bridge Associates International Pharmaceutical Consulting in March 2020. He is the former director of Sales for Mesa Labs (MLAB) in Denver CO, a Nasdaq listed corporation that specializes in providing quality control products and services to ensure the safety and efficacy of equipment used in hospitals, pharmaceutical, medical device manufacturers, blood banks, laboratories, pharmacies, and industrial facilities.

In July of 1999 he founded Amega Scientific Corporation. He grew the company from a startup operation to a worldwide industry leader. Anthony developed and managed a staff with multiple North American offices, establishing R&D, production, logistics, administration, and sales. Clients included pharmaceutical, biotech, hospitals, government facilities, and research universities. Amega Scientific was a leading innovator for the Environmental Monitoring System industry. Amega Scientific was an ISO 17025 corporation instituting GXP requirements. Amega Scientific was acquired by Mesa Labs in November 2013.

Mr. Amato graduated from Glassboro State College (New Jersey) in 1989, with a dual degree in business management and finance. Mr. Amato’s outstanding interpersonal, business development, team building, and management skills make him an asset to the Company’s board of directors.

Ferdinand Groenewald

Ferdinand Groenewald

Interim CFO

Ferdinand Groenewald is a certified public accountant with significant experience in finance and accounting. He currently serves as Vice President, Finance at Alaunos Therapeutics, Inc. Previously, Mr. Groenewald served as an Independent Outside Director at SYLA Technologies Co., Ltd.; an Independent Director at HeartCore Enterprises, Inc.; an Independent Director at Sushi Ginza Onodera, Inc.; an Accountant at Wrinkle, Gardner & Co. PC; a Senior Staff Accountant at Financial Consulting Strategies LLC; a Controller, VP-Finance & Accounting Officer at Sadot Group, Inc. and a Chief Financial Officer at the same company; and Chief Accounting Officer & VP-Finance at Muscle Maker Development LLC. Mr. Groenewald obtained an undergraduate degree from the University of South Africa.